HCRT and insomnia measurement: The combination of desirable pharmacokinetic and receptor-binding properties as well as a high level of OX2R occupancy necessary to antagonize the wake promoting effects of the endogenous orexin ligand allows DORAs to alleviate insomnia symptoms during normal sleep periods while avoiding residual somnolence during subsequent waking periods.